耐多药肺结核给予卷曲霉素联合左氧氟沙星治疗的价值评价

Evaluation of the treatment of multi drug resistant pulmonary tuberculosis with combined with levofloxacin

目的对卷曲霉素联合左氧氟沙星在耐多药肺结核治疗中的临床价值进行探究。方法从本院2014年1月~2017年1月期间收治的耐多药肺结核患者中抽取60例均等分为对照组(常规化疗)与研究组(卷曲霉素联合左氧氟沙星)。对比不同组别患者痰菌转阴率、治疗前后免疫能力、并发症出现情况。结果研究组治疗3个月、6个月后痰菌转阴率明显比对照组高(P<0.05);治疗前两组患者免疫能力差异无统计学意义,治疗后研究组CD4+、Ig G、Ig A、Ig M水平明显比对照组高,CD8+水平明显比对照组低(P<0.05);两组并发症出现率差异无统计学意义。结论耐多药肺结核给予卷曲霉素联合左氧氟沙星治疗临床效果明显。

Objective To investigate the clinical value ofAspergillus fumigatus combined with levofloxaein in the treatment of multidrug-resistant pulmonary tuberculosis. Methods From January 2014 to January 2017, 60 patients with MDR-TB were divided into control group （routine che- motherapy） and the study group （combined with levofloxacin）. The sputum negative rate, immunity and complications of the patients in different groups were compared. Results The results of the study group after 3 months and 6 months after the sputum negative conversion rate was significandy higher than the control group （P 〈 0.05）; the differences between the two groups of patients before treatment immunity is not obvious, the research group after treatment CD4＋＋, IgG, IgA and IgM levels were significantly higher than the control group, CD8^＋ level obviously lower than the control group （P 〈 0.05）; the rate of complications of the two groups appeared no significant difference. Conclusion The clinical efficacy of multi drug resistant pulmonary tuberculosis treated with Aspergillus and levofloxacin is obvious.